As part of our series focussing on medicines available in Australia, we have added a product review of the use of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-Cell lymphoma (in the second-line setting).
This review summarises current CAR-T options and treatment algorithms, contraindications and a series of clinical studies featuring axicabtagene ciloleucel treatment. It also provides commentary and guidance from Professor Michael Dickinson, Disease Group Lead in Aggressive Lymphoma at the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital.
Please login below to download this issue (PDF)